sirolimus and elaiophylin

Rapamycin is an important macrocyclic antibiotic produced by Streptomyces rapamycinicus. In the rapamycin biosynthetic gene cluster (BGC), there are up to five regulatory genes, which have been shown to play important roles in the regulation of rapamycin biosynthesis. Here, we demonstrated that the rapamycin BGC-situated LAL family regulator RapH co-ordinately regulated the biosynthesis of both rapamycin and elaiophylin. We showed that rapH overexpression not only resulted in enhanced rapamycin production but also led to increased synthesis of another type I polyketide antibiotic, elaiophylin. Consistent with this, rapH deletion resulted in decreased production of both antibiotics. Through real-time RT-PCR combined with β-glucuronidase reporter assays, four target genes controlled by RapH, including rapL (encoding a lysine cyclodeaminase)/rapH in the rapamycin BGC and ela3 (encoding a LuxR family regulator)/ela9 (encoding a hypothetical protein) in the elaiophylin BGC, were identified. A relatively conserved signature sequence recognized by RapH, which comprises two 4-nt inverted repeats separated by 8-nt, 5'-GTT/AC-N

Topics: Bacterial Proteins; Gene Expression Regulation, Bacterial; Macrolides; Multigene Family; Sirolimus; Streptomyces

Streptomyces hygroscopicus ATCC 29253 produces rapamycin, elaiophylin and nigericin. Although elaiophylin has no activity against Candida albicans ATCC 11651, it markedly enhances rapamycin's antifungal activity. Nigericin has only weak activity on its own but it also enhances rapamycin action. Surprisingly, elaiophylin does not enhance nigericin activity on C. albicans.

Topics: Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Dose-Response Relationship, Drug; Drug Therapy, Combination; Inhibitory Concentration 50; Macrolides; Microbial Sensitivity Tests; Nigericin; Sirolimus